Single-cell technologies have positioned themselves at the forefront of biomedical research. These platforms allow researchers to bypass the uncertainties of bulk data and instead interrogate biological systems at a level of detail that was previously unreachable. But the value of these systems risks being impaired by bottlenecks in data analysis and handling. To find out more, we spoke to Marilyn Matz, CEO and co-founder of Paradigm4, an analytics solutions company that aims to provide solutions to these data problems.
